Compare Novo Nordisk A/S (NVO) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs PayPal Holdings, Inc. — how do they compare? Novo Nordisk A/S trades at $38.2 (market cap $168.73B), while PayPal Holdings, Inc. trades at $55.1 (market cap $47.01B). The key difference: Novo Nordisk A/S is far larger — about 3.6× PayPal Holdings, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.7%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and PayPal Holdings, Inc. for 106 Days on average.
| NVO | PYPL | |
|---|---|---|
Market Cap | $168.73B | $47.01B |
Volume | 13,531,267 | 10,493,459 |
Sector | Health | Financials |
52-Week High | $63.98 | $75.75 |
52-Week Low | $35.29 | $39.08 |
Typical Hold Time | 116 Days | 106 Days |
Enterprise Value | $183.05B | $49.15B |
Dividend Yield | 4.7% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
PayPal (PYPL) trades at $54.95, up 0.62% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $56.47. The stock shows strong profitability with a net income margin of 14.36% and ROE of 24.5%, supported by recent earnings beats in Q1 and Q2 2026. A new partnership with Meta's AI agent for checkout services, announced on September 22, 2026, provides a potential growth catalyst amid competitive pressures in digital payments.
PYPL presents a value opportunity with a low P/E of 10.39 and solid cash flow, but faces risks from slowing branded checkout growth and intense fintech competition. The stock's upside hinges on successful execution of Venmo expansion and cost-cutting initiatives under new CEO Enrique Lores, with investor sentiment cautiously optimistic given the 35.71% buy rating from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
